AIM’s Latest Newsletter: The Research Edition, July 2023

Published:  
08/01/2023
Categories:  
Blog - Melanoma360
 | 
Melanoma Research
Image

This month’s newsletter focuses on the latest news and scientific breakthroughs in melanoma research.

This edition features:

  • Letter from AIM’s President, Sam Guild
  • Notes From the Lab: Novel Targets for Immune Checkpoint Inhibitors
    By Paul Bunk, Ph.D. candidate, Cold Springs Harbor Laboratory
  • In Plain English: Neoadjuvant Therapy for Melanoma, and How We Got Here
    By Kim Margolin, M.D., FACP, FASCO
  • Clinical Trials Catch Up: An Interview with Joshua M.V. Mammen, M.D., Ph.D., F.A.C.S.
    By Alicia Rowell, Vice President, AIM at Melanoma

Recent Posts

Featured image for “Melanoma Monday: Every Day. Everywhere.”
May. 04, 2026

Melanoma Monday: Every Day. Everywhere.

Featured image for “Lilly Pulitzer and AIM at Melanoma Partner for 5th Annual Community Giving Event”
Apr. 27, 2026

Lilly Pulitzer and AIM at Melanoma Partner for 5th Annual Community Giving Event

Featured image for “KIMMTRAK doubles the likelihood of being alive at five years for firstline HLA-A*02:01+ patients with metastatic uveal melanoma”
Apr. 19, 2026

KIMMTRAK doubles the likelihood of being alive at five years for firstline HLA-A*02:01+ patients with metastatic uveal melanoma

Featured image for “FDA Does Not Approve RP1 in Combination with Nivolumab for Advanced Melanoma: What This Means for Patients”
Apr. 10, 2026

FDA Does Not Approve RP1 in Combination with Nivolumab for Advanced Melanoma: What This Means for Patients

Featured image for “2026 National Sunscreen Partner”
Apr. 07, 2026

2026 National Sunscreen Partner

Filter by Tag